1-12 of 12
Patrick M. Forde
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3957.
https://doi.org/10.1158/1078-0432.CCR-24-2131
Published: 03 September 2024
View article titled, Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Open the PDF for Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors in another window
Journal Articles

Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer

Joseph C. Murray, Lavanya Sivapalan, Karlijn Hummelink, Archana Balan, James R. White, Noushin Niknafs, Lamia Rhymee, Gavin Pereira, Nisha Rao, Benny Weksler, Nathan Bahary, Jillian Phallen, Alessandro Leal, David L. Bartlett, Kristen A. Marrone, Jarushka Naidoo, Akul Goel, Benjamin Levy, Samuel Rosner, Christine L. Hann, Susan C. Scott, Josephine Feliciano, Vincent K. Lam, David S. Ettinger, Qing Kay Li, Peter B. Illei, Kim Monkhorst, Robert B. Scharpf, Julie R. Brahmer, Victor E. Velculescu, Ali H. Zaidi, Patrick M. Forde, Valsamo Anagnostou
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (2): 389–403.
https://doi.org/10.1158/1078-0432.CCR-23-1469
Published: 17 January 2024
View article titled, Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer
Open the PDF for Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen R. Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (4): 705–710.
https://doi.org/10.1158/1078-0432.CCR-22-2994
Published: 16 February 2023
View article titled, Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Open the PDF for Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors

David S. Hong, Olivier Rixe, Vi K. Chiu, Patrick M. Forde, Tomislav Dragovich, Yanyan Lou, Asha Nayak-Kapoor, Rom Leidner, James N. Atkins, Agron Collaku, Floyd E. Fox, Margaret A. Marshall, Anthony J. Olszanski
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 479–488.
https://doi.org/10.1158/1078-0432.CCR-21-2781
Published: 01 February 2022
View article titled, Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
Open the PDF for Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors in another window
Journal Articles

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bedard, Chia-Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine A. Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (13): 3620–3629.
https://doi.org/10.1158/1078-0432.CCR-20-4746
Published: 01 July 2021
View article titled, Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Open the PDF for Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop

Kristen L. Mueller, Marc R. Theoret, Steven J. Lemery, Laleh Amiri-Kordestani, Charlotte E. Ariyan, Michael B. Atkins, Donald A. Berry, Christian U. Blank, Angela M. DeMichele, Patrick M. Forde, Nageatte Ibrahim, Patricia Keegan, Tara C. Mitchell, Rebecca A. Moss, Caroline Robert, Rajeshwari Sridhara, Janis M. Taube, Michael T. Tetzlaff, Jennifer A. Wargo, Keith T. Flaherty, Michael J. Kaplan, Suzanne L. Topalian, Ashley F. Ward, Marc S. Hurlbert
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (2): 394–401.
https://doi.org/10.1158/1078-0432.CCR-20-3285
Published: 19 January 2021
View article titled, Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop
Open the PDF for Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop in another window
Journal Articles

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer

Jiajia Zhang, Zhicheng Ji, Justina X. Caushi, Margueritta El Asmar, Valsamo Anagnostou, Tricia R. Cottrell, Hok Yee Chan, Prerna Suri, Haidan Guo, Taha Merghoub, Jamie E. Chaft, Joshua E. Reuss, Ada J. Tam, Richard L. Blosser, Mohsen Abu-Akeel, John-William Sidhom, Ni Zhao, Jinny S. Ha, David R. Jones, Kristen A. Marrone, Jarushka Naidoo, Edward Gabrielson, Janis M. Taube, Victor E. Velculescu, Julie R. Brahmer, Franck Housseau, Matthew D. Hellmann, Patrick M. Forde, Drew M. Pardoll, Hongkai Ji, Kellie N. Smith
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1327–1337.
https://doi.org/10.1158/1078-0432.CCR-19-2931
Published: 13 March 2020
View article titled, Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Open the PDF for Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Julie E. Stein, Evan J. Lipson, Tricia R. Cottrell, Patrick M. Forde, Robert A. Anders, Ashley Cimino-Mathews, Elizabeth D. Thompson, Mohamad E. Allaf, Mark Yarchoan, Josephine Feliciano, Hao Wang, Elizabeth M. Jaffee, Drew M. Pardoll, Suzanne L. Topalian, Janis M. Taube
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 545–551.
https://doi.org/10.1158/1078-0432.CCR-19-2379
Published: 03 February 2020
View article titled, Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Open the PDF for Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade in another window
Includes: Supplementary data
Journal Articles

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

Christina S. Baik, Eric H. Rubin, Patrick M. Forde, Janice M. Mehnert, Deborah Collyar, Marcus O. Butler, Erica L. Dixon, Laura Q.M. Chow
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 4992–5002.
https://doi.org/10.1158/1078-0432.CCR-16-3066
Published: 31 August 2017
View article titled, Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities
Open the PDF for Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities in another window
Journal Articles

Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity

Valsamo Anagnostou, Mark Yarchoan, Aaron R. Hansen, Hao Wang, Franco Verde, Elad Sharon, Deborah Collyar, Laura Q.M. Chow, Patrick M. Forde
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 4959–4969.
https://doi.org/10.1158/1078-0432.CCR-16-3065
Published: 31 August 2017
View article titled, Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Open the PDF for Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity in another window
Journal Articles

New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer

Patrick M. Forde, Julie R. Brahmer, Ronan J. Kelly
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (9): 2244–2248.
https://doi.org/10.1158/1078-0432.CCR-13-2088
Published: 30 April 2014
View article titled, New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer
Open the PDF for New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer in another window
Journal Articles

New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice

Patrick M. Forde, Ronan J. Kelly, Julie R. Brahmer
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1067–1073.
https://doi.org/10.1158/1078-0432.CCR-13-0731
Published: 02 March 2014
View article titled, New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
Open the PDF for New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice in another window